biOasis Technologies Inc. | |
Stock Exchange | Other OTC |
EPS |
$0.04 |
Market Cap |
$13.33 M |
Shares Outstanding |
58.59 M |
Public Float |
45.4 M |
biOasis Technologies Inc. | |
Stock Exchange | Toronto Ventures Stock Exchange |
EPS |
CAD0.06 |
Market Cap |
CAD17.06 M |
Shares Outstanding |
45.65 M |
Public Float |
39.73 M |
Address |
14 Water Street Guilford Connecticut 06437 United States |
Employees | - |
Website | http://www.bioasis.ca |
Updated | 07/08/2019 |
biOasis Technologies, Inc. is a biopharmaceutical company focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include Transcend program as its proprietary carrier, p97, and components thereof, to deliver therapeutics and imaging agents across the blood brain barrier. The company was founded by Rob Hutchison on May 3, 2007 and is headquartered in Vancouver, Canada. |